InDex Pharmaceuticals AB

22/05/2024

Yesterday, InDex and Flerie hosted an investor meeting regarding the proposed reverse merger that was announced on May 20. You can watch a recording of the presentations through the link below.

© All rights reserved. Redeye AB is authorised and regulated by the Swedish Financial Supervisory Authority, Finansinspektionen. 2024

21/05/2024

InDex has entered into a conditional agreement regarding a reverse merger with Flerie. For more information please use the link below:

20 May 2024 – InDex Pharmaceuticals Holding AB (publ) (

08/04/2024

Today, InDex Pharmaceuticals Holding AB published the Annual Report for 2023. You can find it on InDex's website.

April 8, 2024 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2023. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports/.

05/04/2024

The notice to the Annual General Meeting in InDex Pharmaceuticals Holding AB are now available on the Company's website.

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting. In case of any discrepancies between the Swedish and English language versions, the Swedish version shall prevail April 5 2024 – Shareholders in InDex Pharmaceuticals Hol...

21/02/2024

Today, InDex Pharmaceuticals published the year-end report for 2023

Full focus on closing phase III program

22/11/2023

InDex Pharmaceuticals announced yesterday that an independent Data Monitoring Committee (DMC) has completed the planned dose selection analysis, including safety review and assessment for futility in Induction Study 1 of the phase III program CONCLUDE.

The DMC advises that cobitolimod is unlikely to meet the primary endpoint upon completion of Induction Study 1. The advice to stop the study was not based on safety concerns.

“This surprising and disappointing news confirms the complexity of the disease and the need for further research within this field, especially as moderate to severe ulcerative colitis is an indication with high unmet medical need for new treatment options. We are incredibly grateful to all the patients, investigators and study personnel for their engagement to date,” says Jenny Sundqvist, CEO of InDex Pharmaceuticals. “We will conduct a comprehensive review of all the study data before announcing next steps.”

Click the link below for more information and login details to an investor call today at 3 pm CET.

· Independent Data Monitoring Committee (DMC) advises that cobitolimod is unlikely to meet the primary endpoint upon completion of Induction Study 1 · More information regarding next steps will be provided once a thorough analysis of the data from Induction Study 1 has been completed 21 November, ...

21/11/2023

We are looking forward to participate at the Redeye Life Science Day 2023 on November 23 at 11:20 CET.

Our CEO, Jenny Sundqvist, will present and be joined by leadership team colleagues to answer questions about the company and our phase III program CONCLUDE, which is evaluating cobitolimod as a novel treatment for patients with moderate to severe, left-sided ulcerative colitis.

Watch the livestream via the link below where the presentation also will be available afterwards.

The presentation will also be available afterwards on InDex Pharmaceuticals' website: www.indexpharma.com

More information below.

On 23 November, we will bring together 40+ Nordic companies for Life Science Day, a live-streamed event where investors, businesses, and experts co-create the industry’s future.

26/10/2023

🙌 InDex stödjer Mag och tarmförbundets fina arbete med att öka kunskapen om sjukdomar i mag-tarmkanalen. Vår utvecklingschef, Eva Arlander, deltog i seminariedagen sondag den 22 oktober som innehöll många goda samtal och bra föredrag.
🙏 Ett varmt tack att vi fick vara med!

23/10/2023

New patent for granted by the Korean Intellectual Property Office. The patent provides protection for the use of cobitolimod in the treatment of inflammatory bowel disease with an exclusivity period until August 2040.

Read more: https://lnkd.in/eyM2EbDr

17/10/2023

InDex team members have been in Copenhagen this week attending United European Gastroenterology Week (UEGW), one of the world’s leading gastroenterology congresses.

The positive results from the pharmacokinetic (PK) study with cobitolimod was selected by UEGW as one of the best abstracts for poster presentation, and was presented at the congress by principal investigator Professor Per Hellström during the moderated poster session: “Medical therapy of IBD: Facts and challenges.”


UEG - United European Gastroenterology

11/10/2023

“We are pleased to announce that the final patient visit needed for the dose selection analysis has occurred. We have seen great progress in the study and an accelerated patient recruitment rate since January this year. We are very grateful to the patients, investigators and study personnel for their time and commitment. We will present the outcome of the dose selection analysis in Q4 this year, as previously communicated.”
Jenny Sundqvist, CEO

Press release: https://www.indexpharma.com/en/index-pharmaceuticals-announces-that-all-patients-needed-for-the-cobitolimod-dose-selection-milestone-have-completed-induction-study-1-of-the-phase-iii-program-conclude/

07/09/2023

✨ If you missed our recent presentation at HC Andersen Capital's Life Science Seminar? No worries! The recording of our presentation is now available via the clickable image link below. 🎥

*Disclaimer: HC Andersen Capital modtager betaling fra selskabet for en Digital IR/Corporate Visibility abonnementsaftale.Indholdet er ikke købs- eller salgs...